헤더 로고

• All
• March 26 (Thu)
• March 27 (Fri)
• March 28 (Sat)

Day 3: March 28 (Sat)

• Current Practice and Research in T-cell and NK/T-cell Lymphoma in Japan Motoko Yamaguchi
  Mie University Graduate School of Medicine, Japan CV Abstract
• Advances in the Diagnosis and Treatment of NK/T-cell Lymphoma: Perspectives and Team Experience Huangming Hong
  Sichuan Cancer Hospital, China CV Abstract
• Clinical and Translational Research in T-cell and NK/T-cell Lymphoma in Korea Seok Jin Kim
  Sungkyunkwan University School of Medicine, Korea CV Abstract

Day 3: March 28 (Sat)

• Ethnic Disparities in Germline Variants of Myeloid Malignancies Young-Uk Cho
  University of Ulsan College of Medicine, Korea CV Abstract
• Inherited Myeloid Malignancies: From Genetic Diagnosis to Clinical Management Marc H.G.P. Raaijmakers
  Erasmus MC Cancer Institute, The Netherlands CV Abstract
• Germline Predisposition Genes in Lymphoid Malignancies Susan L. Slager
  Mayo Clinic, USA CV Abstract

Day 3: March 28 (Sat)

• Immunological Landscape of CML Kyung-Mi Lee
  Korea University College of Medicine, Korea CV Abstract
• Translating Single-Cell Biology into Clinically Actionable Protein Biomarkers in CML Sin Tiong Ong
  Duke-NUS Medical School, Singapore CV Abstract
• Drug Combination to Overcome Resistance in CML Delphine Rea
  Saint-Louis University Hospital, France CV Abstract

Day 3: March 28 (Sat)

• Vaccination and Infection Prevention Seong Jin Choi
  Seoul National University College of Medicine, Korea CV Abstract
• Cardiotoxicity: Risk Assessment and Prevention Hyukjin Park
  Chonnam National University Medical School, Korea CV Abstract
• Chemotherapy-Induced Peripheral Neuropathy Young Woo Jeon
  College of Medicine, The Catholic University of Korea, Korea CV

Day 3: March 28 (Sat)

• High-Risk Multiple Myeloma in 2026: Early Intervention, MRD-Driven Therapy, and Beyond Philippe Moreau
  University Hospital of Nantes, France CV